MITOCHONDRIAL DYSFUNCTION IN NEURODEGENERATIVE DISEASES: FROM ENERGY FAILURE TO NEURONAL DEATH
Keywords:
Keywords: Neuroplasticity, Brain injury, Stroke, Synaptic plasticity, BDNF, Neurorehabilitation, Brain-computer interfaceAbstract
Abstract
Neuroplasticity enables the brain to adapt structurally and functionally after
injury. Following stroke, traumatic brain injury, and other neurological insults,
synaptic remodeling, axonal sprouting, cortical reorganization, and glial responses
contribute to functional recovery. Rehabilitation, neuromodulation, brain-computer
interfaces, and emerging AI-based approaches aim to enhance these adaptive
processes. This review summarizes key mechanisms of post-injury neuroplasticity and
current therapeutic strategies for improving neurological recovery.
References
1. Apostolova, N., & Victor, V. M. (2015). Molecular strategies for targeting
antioxidants to mitochondria: Therapeutic implications. Antioxidants & Redox
Signaling, 22(8), 686–729.
2. Fivenson, E. M., Lautrup, S., Sun, N., Scheibye-Knudsen, M., Stevnsner,
T., Nilsen, H., Bohr, V. A., & Fang, E. F. (2017). Mitophagy in neurodegeneration and
aging. Neurochemistry International, 109, 202–209.
3. Gao, X.-Y., Yang, T., Gu, Y., & Sun, X.-H. (2022). Mitochondrial
dysfunction in Parkinson’s disease: From mechanistic insights to therapy. Frontiers in
Aging Neuroscience, 14, 885500.
4. Johri, A., & Beal, M. F. (2012). Mitochondrial dysfunction in
neurodegenerative diseases. The Journal of Pharmacology and Experimental
Therapeutics, 342(3), 619–630.
5. Klemmensen, M. M., Borrowman, S. H., Pearce, C., Pyles, B., & Chandra,
B. (2024). Mitochondrial dysfunction in neurodegenerative disorders.
Neurotherapeutics, 21(1), e00292.
6. Pantiya, P., Thonusin, C., Chattipakorn, N., & Chattipakorn, S. C. (2020).
Mitochondrial abnormalities in neurodegenerative models and possible interventions:
Focus on Alzheimer’s disease, Parkinson’s disease, Huntington’s disease.
Mitochondrion, 55, 14–47.
7. Wang, Y., Xu, E., Musich, P. R., & Lin, F. (2019). Mitochondrial
dysfunction in neurodegenerative diseases and the potential countermeasure. CNS
Neuroscience & Therapeutics, 25(7), 816–824.
8. Wen, H., Deng, H., Li, B., Chen, J., Zhu, J., Zhang, X., Yoshida, S., &
Zhou, Y. (2025). Mitochondrial diseases: From molecular mechanisms to therapeutic
advances. Signal Transduction and Targeted Therapy, 10, e20443.
9. Williamson, M. G., Madureira, M., McGuinness, W., Heon-Roberts, R.,
Mock, E. D., Naidoo, K., et al. (2023). Mitochondrial dysfunction and mitophagy
defects in LRRK2-R1441C Parkinson’s disease models. Human Molecular Genetics,
32(18), 2808–2821.
10. Zhao, J., Wang, X., Huo, Z., Chen, Y., Liu, J., Zhao, Z., et al. (2022). The
impact of mitochondrial dysfunction in amyotrophic lateral sclerosis. Cells, 11(13),
2049.
